Check Claims Before You Publish

Top-level summary (visual first)

Visual above uses the author's per-year works and cited-by counts (OpenAlex aggregation) to show productive periods (1990s–2000s) and citation peaks (late 1990s–2005), consistent with several influential mechanistic papers that remain widely cited.

What the objective evidence shows

• Publication volume and impact: OpenAlex aggregates indicate ~113 works and ~3,123 cumulative citations with h-index ≈29 (indexing multiple author records; the top OpenAlex identity shows these metrics and an extended per-year distribution used in the figure above).
• High-impact mechanistic contributions: Several highly-cited, experimentally detailed papers anchor the author's influence: a 2005 J Cell Biol mechanistic mast-cell degranulation paper (308 citations) that combined imaging and functional assays to define microtubule-dependent granule translocation J Cell Biol 2005 mast cell degranulation.
• Discovery-to-function pipeline: The author is a first author on a 1998 J Immunol discovery (BASH) and middle author on a 2000 PNAS genetics/functional validation paper showing BASH is required for normal B-cell development, demonstrating a through-line from gene discovery to in vivo functional genetics BASH discovery J Immunol 1998 PNAS 2000 BASH functional genetics.
• Breadth across systems: Contributions span immunology (B cells, mast cells), developmental biology (SMAD1/germ-cell commitment), and mucosal/antimicrobial peptide biology (avian cathelicidin in PNAS 2007). This multi-domain presence indicates methodological versatility and cross-disciplinary collaboration PNAS 2007 cathelicidin-B1.

Strengths (evidence-based)

1. Strong experimental breadth: in vivo genetics, primary cell culture, imaging, and functional assays across multiple studies (examples above show imaging + pharmacology + genetics) J Cell Biol 2005 mechanistic methods.
2. Track record of discovery-to-validation: gene discovery (BASH) followed by functional knockouts and physiological readouts in subsequent work shows scientific follow-through and translational relevance BASH discovery PNAS functional validation.
3. Sustained citation influence during 1990s–2000s peak years (visualized above), consistent with foundational contributions used by other labs (multiple papers >100 citations).

Limitations, blindspots and caveats

• Authorship position varies: several high-impact papers list Goitsuka as middle-author; while valuable, middle authorship reduces direct attribution of conceptual leadership for those specific studies — assess individual papers for lead-author conceptual claims.
• Heterogeneous topic coverage: breadth is a strength but reduces deep ownership of a single, narrowly-defined program; users should judge individual works on methods and reproducibility rather than aggregate counts alone.
• Open-data and reproducibility: many older studies predate modern data‑sharing norms; while some recent work (e.g., scRNA-seq in 2026 MEIS1 paper) deposits raw data and code, not all records have machine-accessible raw data — check paper-specific availability before reanalysis MEIS1 2026 scRNA-seq data deposition.
• Potential bibliographic conflation: multiple OpenAlex author records exist for variants of the name; the top record aggregates 113 works but minor records indicate other smaller clusters — confirm the identity/orcid when evaluating authorship credit.

Practical recommendations for evaluating Goitsuka's work

1. When assessing specific claims, read the methods and quantified replicates (many high-impact papers include detailed methods and orthogonal validation); prefer lead-author papers for conceptual claims.
2. Use the citation network: trace downstream papers citing the 1998–2005 core works to see how their conclusions were reused, extended, or corrected (citation context matters more than counts alone).
3. For modern reanalysis, focus on recent, data-rich papers that provide raw data (e.g., 2026 MEIS1 scRNA-seq) to enable reproducibility checks and new analyses MEIS1 2026 data-rich example.

Representative influential papers (quick evidence links)

• J Cell Biol 2005 mechanistic mast-cell degranulation (multi-method experimental depth) J Cell Biol 2005
• PNAS 2000 BASH functional genetics (in vivo validation) PNAS 2000
• PNAS 2007 chicken cathelicidin-B1 (mucosal immunology) PNAS 2007

Conclusions & confidence

Ryo Goitsuka is a productive experimental biologist with several widely-cited, methodologically robust papers that contributed mechanistic insight in immunology and developmental biology; his record shows discovery-to-validation pathways and sustained influence especially in the 1990s–2000s. For current, reproducible reanalysis use recent data-rich papers (e.g., 2026 MEIS1 scRNA-seq) that provide raw data and code MEIS1 2026 example.